(Q44397625)

English

Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).

scientific article published in April 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). (English)

1 reference

Europe PubMed Central

2 December 2017

Christopher P Cannon

7

object named as

Christopher P Cannon

1 reference

Europe PubMed Central

2 December 2017

Sabina A Murphy

3

object named as

Sabina A Murphy

1 reference

Europe PubMed Central

2 December 2017

author name string

Duane S Pinto

1

1 reference

Europe PubMed Central

2 December 2017

David P Lorenz

2

1 reference

Europe PubMed Central

2 December 2017

Susan J Marble

4

1 reference

Europe PubMed Central

2 December 2017

Peter M DiBattiste

5

1 reference

Europe PubMed Central

2 December 2017

Laura A Demopoulos

6

1 reference

Europe PubMed Central

2 December 2017

C Michael Gibson

8

1 reference

Europe PubMed Central

2 December 2017

TIMI Study Group

9

1 reference

Europe PubMed Central

2 December 2017

language of work or name

0 references

publication date

1 April 2003

1 reference

Europe PubMed Central

2 December 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

2 December 2017

91

1 reference

Europe PubMed Central

2 December 2017

976-8, A4

1 reference

Europe PubMed Central

2 December 2017

8

1 reference

Europe PubMed Central

2 December 2017

Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Relation between activated clotting time during angioplasty and abrupt closure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Heparin dosing in patients undergoing coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

In vivo demonstration of an antithrombin effect of abciximab

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900117-6

7 January 2021

Identifiers

10.1016/S0002-9149(03)00117-6

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44397625&oldid=2086503133"